<![CDATA[Biotek-snakken — Februar 2026]]>
Link Preview Image
Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency - Egetis Therapeutics

Priority Review and Rare Pediatric Disease Priority Review Voucher requested Anticipated regulatory decision in September 2026 Emcitate® (tiratricol) U.S. launch expected in Q4 2026, if approved Stockholm, Sweden, January 29, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced that the Company has completed the rolling New Drug Application (NDA) […]

favicon

Egetis Therapeutics (www.egetis.com)

]]>https://dev.proinvestor.com/forum/topic/401464/biotek-snakken-februar-2026RSS for NodeSat, 06 Jun 2026 05:03:13 GMTSun, 01 Feb 2026 10:02:27 GMT60<![CDATA[Reply to Biotek-snakken — Februar 2026 on Fri, 27 Feb 2026 06:29:57 GMT]]>Gubra tidoblede omsætningen efter milliardaftale med Abbvie https://proinvestor.com/investornyt/1415516/gubra-tidoblede-omsaetningen-efter-milliardaftale-med-abbvie

]]>https://dev.proinvestor.com/forum/post/8068696https://dev.proinvestor.com/forum/post/8068696Fri, 27 Feb 2026 06:29:57 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Thu, 26 Feb 2026 19:38:11 GMT]]>Ja, den lader vente på sig. 😞

]]>https://dev.proinvestor.com/forum/post/8068695https://dev.proinvestor.com/forum/post/8068695Thu, 26 Feb 2026 19:38:11 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Thu, 26 Feb 2026 18:51:57 GMT]]>Ja nu mangler vi en godkendelse i Mexico, så er vi på rette kurs igen...

]]>https://dev.proinvestor.com/forum/post/8068698https://dev.proinvestor.com/forum/post/8068698Thu, 26 Feb 2026 18:51:57 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Thu, 26 Feb 2026 14:16:28 GMT]]>der er hvis nogen der ikke er klar over den kæmpe forskel i tallene skyldtes den store udlicenserings betaling de fik sidste år ?

]]>https://dev.proinvestor.com/forum/post/8068697https://dev.proinvestor.com/forum/post/8068697Thu, 26 Feb 2026 14:16:28 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Thu, 26 Feb 2026 08:15:02 GMT]]>😞

]]>https://dev.proinvestor.com/forum/post/8068694https://dev.proinvestor.com/forum/post/8068694Thu, 26 Feb 2026 08:15:02 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Thu, 26 Feb 2026 08:14:49 GMT]]>Saniona falder over 16%. 😉

]]>https://dev.proinvestor.com/forum/post/8068692https://dev.proinvestor.com/forum/post/8068692Thu, 26 Feb 2026 08:14:49 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Thu, 26 Feb 2026 08:12:03 GMT]]>Saniona årsrapport 2025. https://saniona.com/newsroom/press-releases/

]]>https://dev.proinvestor.com/forum/post/8068693https://dev.proinvestor.com/forum/post/8068693Thu, 26 Feb 2026 08:12:03 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Sun, 22 Feb 2026 09:22:33 GMT]]>Er der nogen som følger Corvus Pharmaceuticals - interessant ITK inhibitor de har på vej.

]]>https://dev.proinvestor.com/forum/post/8068685https://dev.proinvestor.com/forum/post/8068685Sun, 22 Feb 2026 09:22:33 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Sat, 21 Feb 2026 17:53:00 GMT]]>Saniona afholder investor konference 26 Feb. https://saniona.com/newsroom/single-press-release/?slug=invitation-to-saniona-q4-and-year-end-investor-call-on-26-february-2026

]]>https://dev.proinvestor.com/forum/post/8068690https://dev.proinvestor.com/forum/post/8068690Sat, 21 Feb 2026 17:53:00 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Thu, 19 Feb 2026 09:10:08 GMT]]>Initiator Pharma ser ud til at være på vej mod et breakout nu, og handles stadig under emissionskursen på 4 kr. Det kan blive interessant at følge Q2/Q3.

]]>https://dev.proinvestor.com/forum/post/8068687https://dev.proinvestor.com/forum/post/8068687Thu, 19 Feb 2026 09:10:08 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Wed, 18 Feb 2026 13:10:50 GMT]]>Initiator Pharma A/S granted European patent for pudafensine in Female Sexual Dysfunction, including vulvodynia
https://www.nordnet.dk/markedet/nyheder/2eb95538-e9a8-4e13-85c7-ae0ecc7583aa

]]>https://dev.proinvestor.com/forum/post/8068686https://dev.proinvestor.com/forum/post/8068686Wed, 18 Feb 2026 13:10:50 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Wed, 18 Feb 2026 05:06:53 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8068684https://dev.proinvestor.com/forum/post/8068684Wed, 18 Feb 2026 05:06:53 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Wed, 18 Feb 2026 04:51:09 GMT]]>Godmorgen 🙂

]]>https://dev.proinvestor.com/forum/post/8068683https://dev.proinvestor.com/forum/post/8068683Wed, 18 Feb 2026 04:51:09 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Tue, 17 Feb 2026 06:58:46 GMT]]>@Darvin - Ja; Curasight ligger ikke på den lade sig - Dagens udmelding om deltagelse i TD Cowen konferencen 3. marts med pæsentation og 1-1 møder lyder spændende. De fisker efter partneraftale. https://news.cision.com/curasight/r/curasight-to-present-at-td-cowen-s-46th-annual-health-care-conference-in-boston,c4308454

]]>https://dev.proinvestor.com/forum/post/8068688https://dev.proinvestor.com/forum/post/8068688Tue, 17 Feb 2026 06:58:46 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Tue, 10 Feb 2026 08:18:51 GMT]]>PILA PHARMA AB (publ) (FN STO: PILA) today publishes the Company´s
year-end report for the period January – December 2025 https://cdn.bequoted.com/media/1/2e08febe-36c8-4704-bcd7-199fa6b0e831/Pila_Pharma_Pressrelease_2026-02-10.pdf

]]>https://dev.proinvestor.com/forum/post/8068691https://dev.proinvestor.com/forum/post/8068691Tue, 10 Feb 2026 08:18:51 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Tue, 03 Feb 2026 13:32:09 GMT]]>Vil lige nævne en af mine aktier igen, som ikke rigtig nævnes her. Curasight er såmænd nu steget650% siden sommeren 2025. Selv tror jeg der er en rimelig sandsynlighed for at det gentages. Men! Vurder selv!,,

]]>https://dev.proinvestor.com/forum/post/8068682https://dev.proinvestor.com/forum/post/8068682Tue, 03 Feb 2026 13:32:09 GMT<![CDATA[Reply to Biotek-snakken — Februar 2026 on Sun, 01 Feb 2026 10:02:42 GMT]]>Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency

January 29, 2026

Priority Review and Rare Pediatric Disease Priority Review Voucher requested

Anticipated regulatory decision in September 2026

Emcitate® (tiratricol) U.S. launch expected in Q4 2026, if approved

]]>https://dev.proinvestor.com/forum/post/8068689https://dev.proinvestor.com/forum/post/8068689Sun, 01 Feb 2026 10:02:42 GMT